EU Greenlights Device for Outpatient Bladder Cancer Treatment

GOTHENBURG, Sweden – May 05, 2026 – By Kevin Lee

European cancer care is on the verge of a significant transformation following the CE Mark approval of the Multi4 System, a revolutionary device that moves bladder cancer treatment from the hospital operating room to a simple outpatient clinic. The Swedish medtech firm Multi4 Medical announced the regulatory milestone today, opening the door for its all-in-one technology to be deployed across Europe, promising to treat patients in minutes while they are awake.

This approval marks a paradigm shift in urologic oncology. The current standard for non-muscle-invasive bladder cancer involves transurethral resection of a bladder tumor (TURBT), a procedure requiring an operating room, general or spinal anesthesia, and often a hospital stay. With the Multi4 System, what was once a scheduled surgery can now be performed immediately upon detection during a routine office visit.

"The CE mark is a historic milestone for Multi4 Medical and for cancer care in Europe," said Dr. Miden Melle-Hannah, a urologist and the CEO of Multi4 Medical. "The Multi4 instrument integrates all necessary functions into a single compact device and is the first system where cancer tissue is automatically transported out through the instrument itself and captured in a container. This makes treatment streamlined, safe, and feasible in an outpatient setting."

A New Standard for Patient Care

The Multi4 System's design is a feat of integrated engineering. The single, compact instrument allows a urologist to endoscopically perform the entire procedure on an awake patient. It first applies local anesthesia directly to the tumor, then precisely resects the cancerous tissue. Uniquely, the resected tissue is automatically suctioned out through the instrument and collected in an external container, ready for immediate pathological analysis. The device can also cauterize tissue to stop any bleeding, ensuring a clean and controlled procedure.

For patients, the benefits are profound. The system eliminates the long, anxious waits for scheduled surgery, the risks associated with general anesthesia, and the need for post-operative catheterization or hospital admission. Patients can go home immediately after the procedure, which takes only minutes to complete. A clinical investigation involving 18 patients at Sweden's Sahlgrenska University Hospital, which supported the CE mark application, showed excellent results. Earlier reports from the study noted that patients experienced minimal pain and unanimously preferred the new method over the conventional TURBT they had previously undergone.

Tackling a Costly Disease

Beyond the significant improvements to patient quality of life, the Multi4 System addresses a major economic burden on healthcare systems. Bladder cancer is the fifth most common cancer in Europe, with over 200,000 new cases diagnosed annually. It carries the distinction of having the highest lifetime treatment cost per patient of any cancer, largely due to high recurrence rates that necessitate frequent and invasive surveillance.

Inpatient care has historically been a primary driver of these costs, with some estimates placing the total healthcare expenditure for bladder cancer in the EU at nearly €5 billion annually. By shifting the treatment of recurrent, non-muscle-invasive tumors to an outpatient setting, the Multi4 System has the potential to drastically reduce costs associated with operating room time, anesthesia, and hospital bed occupancy. This efficiency not only saves money but also frees up critical hospital resources for more complex cases, a key priority for healthcare systems across the continent.

A Global Strategy with Dual Regulatory Wins

Multi4 Medical's CE Mark approval is the culmination of a remarkable year of regulatory success. The European green light comes just months after the company received FDA clearance for the Multi4 System in the United States. Achieving these two major regulatory approvals in quick succession is a rare feat in the medical device industry and speaks to the technology's robustness and the company's strategic execution.

"Multi4 Medical is an excellent example of world-class Swedish medtech innovation," commented Erik Selin, the company's Chairman of the Board. "That the company now has both FDA clearance and CE mark demonstrates impressive execution capability."

While the CE Mark provides access to the European market, the path to widespread adoption involves navigating the continent's diverse and often complex national healthcare systems. Reimbursement is a critical next step. Although the company states the system is supported by an established reimbursement code, securing favorable coverage and payment policies from national health technology assessment (HTA) bodies in key markets like Germany, France, and the UK will be crucial for rapid uptake.

The Future of Outpatient Oncology

Bolstered by strong investor confidence, including from Chairman Erik Selin and a recent SEK 29 million funding round, Multi4 Medical is well-positioned for its global commercial launch. The company has fostered strong strategic partnerships with Sahlgrenska University Hospital and the RISE Research Institutes of Sweden, which have been instrumental in the device's development and validation.

The company is not stopping with bladder cancer. With its core automated technology for tissue diagnostics and treatment, Multi4 Medical is already collaborating with Karolinska University Hospital to develop new instruments for other cancer types, including those affecting the esophagus and colon. This forward-looking approach suggests that the shift from operating room to outpatient clinic may soon extend beyond urology, underscoring the technology's potential to redefine treatment paradigms across multiple fields of oncology.